stockrowAxoGen, Inc.
AXGN Healthcare Medical Devices
AxoGen, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $225.2 million, up 20.2% from fiscal 2024.
- Revenue
- +26.2%
- EPS
- +163.2%
- Free cash flow
- +995.0%
- Total debt
- −73.1%
Quarter to September 2026, against a year earlier
Follow AXGN
Alert me
AxoGen, Inc. (AXGN) EV/FCF
As of 5 November 2026, AxoGen, Inc. (AXGN) trades at a EV/FCF of 118×. Over the past ten years it has ranged from −3,949× (March 2025) to 83,566× (February 2025); the current reading is higher than 89% of that period.
EV/FCF, daily
Embed this chart
Annual newest first
| Period | EV/FCF | Change |
|---|---|---|
| FY2025 | −320× | — |
| FY2024 | 68,961× | — |
| FY2023 | −15.9× | — |
| FY2022 | −11.5× | — |
| FY2021 | −8.7× | — |
| FY2020 | −20.4× | — |
| FY2019 | −24.0× | — |
| FY2018 | −26.0× | — |
| FY2017 | −87.3× | — |
| FY2016 | −21.6× | — |
Quarterly newest first
| Period | EV/FCF | Change |
|---|---|---|
| Sep 2026 | 99.0× | (72.82%) |
| Jun 2026 | 364× | 71.49% |
| Mar 2026 | 212× | — |
| Dec 2025 | −320× | — |
| 43 more quarters | Free account |
Against its own ten years
EV/FCF against peers
| Company | EV/FCF |
|---|---|
| ESTA Establishment Labs Holdings Inc. compare | −51.7× |
| ALMR Alamar Biosciences, Inc. compare | −14.9× |
| INSP Inspire Medical Systems, Inc. compare | 16.4× |
| UFPT UFP Technologies, Inc. compare | 38.7× |
| TMDX TransMedics Group, Inc. compare | 62.5× |
| NEOG Neogen Corporation compare | 63.4× |
| ITGR Integer Holdings Corporation compare | 68.9× |
| AXGN AxoGen, Inc. | 118× |
| IRTC iRhythm Holdings, Inc. compare | 598× |
What EV/FCF is
EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))
More on AXGN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement